Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Shuster

Showing results (501-510 of 513) with videos related to

Pageof 52
Sort By:
Biochemistry|August 25, 2004
Selective Itk inhibitors block T-cell activation and murine lung inflammationTai-An Lin, Kim W McIntyre, Jagabandhu Das, et al.
Journal of Medicinal Chemistry|December 13, 2007
Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitorsJohn Hynes, Alaric J Dyckman, Shuqun Lin, et al.
Journal of Medicinal Chemistry|May 17, 2002
Discovery of N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-4- morpholineacetamide as a novel and potent inhibitor of inosine monophosphate dehydrogenase with excellent in vivo activityT G Murali Dhar, Zhongqi Shen, Junqing Guo, et al.
Leukemia|April 12, 2003
Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangementsC-H Pui, J M Chessells, B Camitta, et al.
Bioorganic & Medicinal Chemistry Letters|September 4, 2020
Tricyclic sulfones as potent, selective and efficacious RORγt inverse agonists - Exploring C6 and C8 SAR using late-stage functionalizationQing Shi, Zili Xiao, Michael G Yang, et al.
Journal of Medicinal Chemistry|September 1, 2010
Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseasesChunjian Liu, James Lin, Stephen T Wrobleski, et al.
Journal of Medicinal Chemistry|December 2, 2020
Biologic-like In Vivo Efficacy with Small Molecule Inhibitors of TNFα Identified Using Scaffold Hopping and Structure-Based Drug Design ApproachesHai-Yun Xiao, Ning Li, James J-W Duan, et al.
ACS Medicinal Chemistry Letters|May 31, 2021
Azatricyclic Inverse Agonists of RORγt That Demonstrate Efficacy in Models of Rheumatoid Arthritis and PsoriasisQingjie Liu, Hai-Yun Xiao, Douglas G Batt, et al.
Journal of Medicinal Chemistry|November 30, 2004
The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinaseKaterina Leftheris, Gulzar Ahmed, Ran Chan, et al.
The Cleft Palate-Craniofacial Journal : Official Publication of the American Cleft Palate-Craniofacial Association|June 12, 2010
Otologic and audiologic outcomes with the Furlow and von Langenbeck with intravelar veloplasty palatoplasties in unilateral cleft lip and palatePatrick J Antonelli, José C Jorge, Mariza R Feniman, et al.
Pageof 52

Showing results (501-510 of 513) with videos related to

Sort By:
Pageof 52
Biochemistry|August 25, 2004
Selective Itk inhibitors block T-cell activation and murine lung inflammationTai-An Lin, Kim W McIntyre, Jagabandhu Das, et al.
Journal of Medicinal Chemistry|December 13, 2007
Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitorsJohn Hynes, Alaric J Dyckman, Shuqun Lin, et al.
Journal of Medicinal Chemistry|May 17, 2002
Discovery of N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-4- morpholineacetamide as a novel and potent inhibitor of inosine monophosphate dehydrogenase with excellent in vivo activityT G Murali Dhar, Zhongqi Shen, Junqing Guo, et al.
Leukemia|April 12, 2003
Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangementsC-H Pui, J M Chessells, B Camitta, et al.
Bioorganic & Medicinal Chemistry Letters|September 4, 2020
Tricyclic sulfones as potent, selective and efficacious RORγt inverse agonists - Exploring C6 and C8 SAR using late-stage functionalizationQing Shi, Zili Xiao, Michael G Yang, et al.
Journal of Medicinal Chemistry|September 1, 2010
Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseasesChunjian Liu, James Lin, Stephen T Wrobleski, et al.
Journal of Medicinal Chemistry|December 2, 2020
Biologic-like In Vivo Efficacy with Small Molecule Inhibitors of TNFα Identified Using Scaffold Hopping and Structure-Based Drug Design ApproachesHai-Yun Xiao, Ning Li, James J-W Duan, et al.
ACS Medicinal Chemistry Letters|May 31, 2021
Azatricyclic Inverse Agonists of RORγt That Demonstrate Efficacy in Models of Rheumatoid Arthritis and PsoriasisQingjie Liu, Hai-Yun Xiao, Douglas G Batt, et al.
Journal of Medicinal Chemistry|November 30, 2004
The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinaseKaterina Leftheris, Gulzar Ahmed, Ran Chan, et al.
The Cleft Palate-Craniofacial Journal : Official Publication of the American Cleft Palate-Craniofacial Association|June 12, 2010
Otologic and audiologic outcomes with the Furlow and von Langenbeck with intravelar veloplasty palatoplasties in unilateral cleft lip and palatePatrick J Antonelli, José C Jorge, Mariza R Feniman, et al.
Pageof 52